Tandem Diabetes Care (TNDM) Assets Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.53% |
| Dec 31, 2025 | -5.76% |
| Sep 30, 2025 | -5.83% |
| Jun 30, 2025 | -5.47% |
| Mar 31, 2025 | -3.16% |
| Dec 31, 2024 | 2.25% |
| Sep 30, 2024 | 4.05% |
| Jun 30, 2024 | 5.64% |
| Mar 31, 2024 | 7.65% |
| Dec 31, 2023 | 9.97% |
| Sep 30, 2023 | 11.78% |
| Jun 30, 2023 | 15.39% |
| Mar 31, 2023 | 40.59% |
| Dec 31, 2022 | 47.79% |
| Sep 30, 2022 | 52.97% |
| Jun 30, 2022 | 59.58% |
| Mar 31, 2022 | 67.85% |
| Dec 31, 2021 | 63.71% |
| Sep 30, 2021 | 67.29% |
| Jun 30, 2021 | 71.38% |
| Mar 31, 2021 | 73.39% |
| Dec 31, 2020 | 95.86% |
| Sep 30, 2020 | 97.04% |
| Jun 30, 2020 | 84.24% |
| Mar 31, 2020 | 44.96% |
| Dec 31, 2019 | 42.63% |
| Sep 30, 2019 | 47.97% |
| Jun 30, 2019 | 32.69% |
| Mar 31, 2019 | 21.18% |
| Dec 31, 2018 | 18.26% |
| Sep 30, 2018 | 12.22% |
| Jun 30, 2018 | 3.78% |
| Mar 31, 2018 | -2.29% |
| Dec 31, 2017 | -3.61% |
| Sep 30, 2017 | -8.95% |
| Jun 30, 2017 | -8.83% |
| Mar 31, 2017 | -7.49% |
| Dec 31, 2016 | -11.51% |